Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL10414999 | 0.92 | MAPT (0.41) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL11422311 | 0.91 | MAPT (0.42) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL11744970 | 0.87 | MAPT (0.40) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL1445124 | 0.84 | TP53 (0.38) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL2095563 | 0.84 | TP53 (0.38) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL20359693 | 0.84 | DNMT1 (0.39) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL21805762 | 0.84 | MAPT (0.40) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL4608905 | 0.84 | DNMT1 (0.43) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL8585531 | 0.83 | HTT (0.37) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL10584873 | 0.82 | DNMT1 (0.44) | TP53MAPTSTAT3HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441259-B2 | Formation of immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-2225388-B1 | COMPOSITIONS FOR FORMING IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150275261-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-8986526-B2 | Formation of immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2235513-B1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130112558-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8389042-B2 | Formation of immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120270756-A1 | FORMATION OF IMMOBILIZED BIOLOGICAL LAYERS FOR SENSING | ABBOTT POINT OF CARE INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8268604-B2 | Compositions for forming immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8241697-B2 | Formation of immobilized biological layers for sensing | ABBOTT POINT OF CARE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20050167269-A1 | System for pH-neutral stable electrophoresis gel | Life Technologies Corporation | 2005-08-04 | — | — | US | disclosed |
| US-20050167268-A1 | System for pH-neutral stable electrophoresis gel | Life Technologies Corporation | 2005-08-04 | — | — | US | disclosed |
| US-6783651-B1 | System for pH-neutral stable electrophoresis gel | INVITROGEN CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20030127330-A1 | System for pH-neutral stable electrophoresis gel | INVITROGEN CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-20030121784-A1 | System for pH-neutral stable electrophoresis gel | INVITROGEN CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-6162338-A | System for pH-neutral stable electrophoresis gel | NOVEX (US) | 2000-12-19 | — | — | US | disclosed |
| US-6143154-A | System for PH-neutral stable electrophoresis gel | NOVEX (US) | 2000-11-07 | — | — | US | disclosed |
| US-6096182-A | System for pH-neutral stable electrophoresis gel | NOVEX (US) | 2000-08-01 | — | — | US | disclosed |
| US-6059948-A | System for pH-neutral stable electrophoresis gel | NOVEX (US) | 2000-05-09 | — | — | US | disclosed |
| US-5922185-A | System for pH-neutral stable electrophoresis gel | NOVEL EXPERIMENTAL TECHNOLOGY, INC. (US) | 1999-07-13 | — | — | US | disclosed |